相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions
Shashank Joshi et al.
CLINICAL PHARMACOKINETICS (2020)
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the Cardiac Benefits of Empagliflozin Independent of its Hypoglycemic Activity?
Carlos G. Santos-Gallego et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Remogliflozin Etabonate: First Global Approval
Anthony Markham
DRUGS (2019)
RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2019 EXECUTIVE SUMMARY
Hector E. Tamez-Perez et al.
ENDOCRINE PRACTICE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Yan Zheng et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Chang-Ik Choi
MOLECULES (2016)
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences
Awadhesh Kumar Singh et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes
A. P. Sykes et al.
DIABETES OBESITY & METABOLISM (2015)
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes
A. P. Sykes et al.
DIABETES OBESITY & METABOLISM (2015)
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Robin O'Connor-Semmes et al.
DRUG METABOLISM AND DISPOSITION (2015)
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula et al.
CLINICAL PHARMACOKINETICS (2014)
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
Antonella Napolitano et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2014)
Regional gastrointestinal delivery of remogliflozin etabonate in humans
Robin L. O'Connor-Semmes et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Anita Kapur et al.
BMC PHARMACOLOGY & TOXICOLOGY (2013)
Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects
Zhuang Miao et al.
DRUG METABOLISM AND DISPOSITION (2013)
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
Sunder Mudaliar et al.
DIABETES CARE (2012)
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
R. L. Dobbins et al.
DIABETES OBESITY & METABOLISM (2012)
Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies
James F. Sigafoos et al.
DRUG METABOLISM AND DISPOSITION (2012)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
分享论文
